Compact, synthetic, vaccinia virus early/late promoter for protein expression

BioTechniques

Volumn 23, Issue 6, 1997, Pages 1094-1097

  Chakrabarti, Sekhar ^a   Sisler, Jerry R ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; THYMIDINE KINASE;

ARTICLE; EXPRESSION VECTOR; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REGULATOR GENE; SEQUENCE ANALYSIS; VACCINIA VIRUS; VIRUS REPLICATION;

MAMMALIA; POXVIRIDAE; VACCINIA; VACCINIA VIRUS;

EID: 0030862430     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/97236st07     Document Type: Article

References (17)

1. Blasco, R. and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162.
2. Bronte, V., M.W. Carroll, T.J. Goletz, M. Wang, W.W. Overwijk, F. Marincola, S.A. Rosenberg, B. Moss and N.P. Restifo. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA 93:3183-3188.
3. Chakrabarti, S., K. Breching and B. Moss. 1985. Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403-3409.
4. Cochran, M.A., C. Puckett and B. Moss. 1985. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J. Virol. 54:30-37.
5. Coupar, B.E.H., M.E. Andre, G.W. Both and D.B. Boyle. 1986. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 76:1479-1487.
6. Davison, A.J. and B. Moss. 1990. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res. 18:4285-4286.
7. Davison, A.J. and B. Moss. 1989. The structure of vaccinia virus early promoters. J. Mol. Biol. 210:749-769.
8. Davison, A.J. and B. Moss. 1989. The structure of vaccinia virus late promoters. J. Mol. Biol. 270:771-784.
9. Earl, P.L. and B. Moss. 1991. Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.16. In FM. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith and K. Struhl (Eds.), Current Protocols in Molecular Biology, Vol. 2. Greene Publishing Associates & Wiley Interscience, New York.
10. Falkner, F.G. and B. Moss. 1988. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 62:1849-1854.
11. Mackett, M., G.L. Smith and B. Moss. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:857-864.
12. Mackett, M., G.L. Smith and B. Moss. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. USA 79:7415-7419.
13. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
14. Moss, B. 1996. Poxviridae:the viruses and their replication, p. 2637-2671. In B.N. Fields, D.M. Knipe and P.M. Howley (Eds.), Fields Virology, 3rd ed., Vol. 2. Lippincott-Raven Publishers, Philadelphia.
15. Panicali, D. and E. Paoletti. 1982. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. USA 79:4927-4931.
16. Rosel, J.L., P.L. Earl, J.P. Weir and B. Moss. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J. Virol. 60:436-439.
17. Sutter, G., L.S. Wyatt, P.L. Foley, J.R. Bennink and B. Moss. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 72:1032-1040.